In early October, the Nearmedic Group presented the latest test system SARS-COV-2-RBD-ELISA-GAMALEI designed for testing protective immunity to the SARS-CoV-2 virus at two authoritative conferences for the scientific and medical community.
On October 6, Pyotr Dmitriev, head of business development at Nearmedic Group, spoke about the SARS-COV-2-RBD-ELISA-GAMALEI test system at the XXVIII International Science and Practice Conference «News of transfusiology: regulatory documents and technologies». And on October 8, Alena Glushakova, Chief Physician at the South-Eastern cluster of the Doctor Next Door network of clinics, delivered a presentation «New promising ELISA test for assessing protective immunity to SARS-CoV-2» in the framework of the online conference «Molecular diagnostics and biosafety 2020».
The principle of operation of the unique test system developed by the N. F. Gamalei National Research Center is based on the enzyme-linked analysis of class G immunoglobulins to the receptor-binding domain (RBD) of the surface glycoprotein S (spike) of the SARS-CoV-2 coronavirus. The SARS-COV-2-RBD-ELISA-GAMALEA test system detects with a high degree of specificity the virus-neutralizing anti-RBD antibodies in the patient’s blood serum that guarantee that protective immunity has been formed.
«This is important for assessing the risk of re—infection and for determining the need for vaccination of the patient, as well as for selecting donors for the treatment of patients with severe coronavirus infection,» explains Alyona Glushakova.
Mass production of unique SARS-COV-2-RBD-ELISA-Gamalei diagnostic kits started this fall at the production site of the Nearmedic Plus company.
«Our expertise in diagnostics has allowed us to become a platform for the release of a modern test system, which is designed to facilitate the work of medical personnel, and is of great demand right now, when the number of patients with SARS-CoV-2 is steadily growing,» says Pyotr Dmitriev.
As part of the specialized exhibition «News of Transfusiology: regulatory documents and technologies», the Nearmedik Group, along with the SARS-COV-2-RBD-ELISA-GAMALEI test system, also presented the ARCHITECT i2000SR automatic immunochemical analyzer by Abbott.